Abstract:Zhoumeng Lin, 1– 4, &ast Wei-Chun Chou, 1– 4, &ast Yi-Hsien Cheng, 3, 4 Chunla He, 5 Nancy A Monteiro-Riviere, 6, 7 Jim E Riviere 7, 8 1 Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA; 2 Center for Environmental and Human Toxicology, University of Florida, Gainesville, FL, USA; 3 Institute of Computational Comparative Medicine, Kansas State University, Manhattan, KS, USA; 4 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA; 5 Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA; 6 Nanotechnology Innovation Center of Kansas State, Kansas State University, Manhattan, KS, USA; 7 Center for Chemical Toxicology Research and Pharmacokinetics, North Carolina State University, Raleigh, NC, USA; 8 1Data Consortium, Kansas State University, Olathe, KS, USA &astThese authors contributed equally to this work Correspondence: Zhoumeng Lin, Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, 1225 Center Dr., Gainesville, FL, 32610, USA, Tel +1 352-273-6160, Email Background: Low delivery efficiency of nanoparticles (NPs) to the tumor is a critical barrier in the field of cancer nanomedicine. Strategies on how to improve NP tumor delivery efficiency remain to be determined. Methods: This study analyzed the roles of NP physicochemical properties, tumor models, and cancer types in NP tumor delivery efficiency using multiple machine learning and artificial intelligence methods, using data from a recently published Nano-Tumor Database that contains 376 datasets generated from a physiologically based pharmacokinetic (PBPK) model. Results: The deep neural network model adequately predicted the delivery efficiency of different NPs to different tumors and it outperformed all other machine learning methods; including random forest, support vector machine, linear regression, and bagged model methods. The adjusted determination coefficients (R 2 ) in the full training dataset were 0.92, 0.77, 0.77 and 0.76 for the maximum delivery efficiency (DE max ), delivery efficiency at 24 h (DE 24 ), at 168 h (DE 168 ), and at the last sampling time (DE Tlast ). The corresponding R 2 values in the test dataset were 0.70, 0.46, 0.33 and 0.63, respectively. Also, this study showed that cancer type was an important determinant for the deep neural network model in predicting the tumor delivery efficiency across all endpoints (19– 29%). Among all physicochemical properties, the Zeta potential and core material played a greater role than other properties, such as the type, shape, and targeting strategy. Conclusion: This study provides a quantitative model to improve the design of cancer nanomedicine with greater tumor delivery efficiency. These results help to improve our understanding of the causes of low NP tumor delivery efficiency. This study demonstrates the feasibility of integrating artificial intelligence with PBPK modeling approaches to study cancer nanomedicine. Graphical Keywords: artificial intelligence, machine learning, physiologically based pharmacokinetic modeling, nanomedicine, drug delivery, nanotechnology Graphical Global Cancer Statistics estimated that almost 10 million deaths occurred worldwide due to cancer in 2020. 1 The treatment of cancer remains a challenge. Traditional small molecule-based chemotherapy has limitations; such as adverse side effects, low therapeutic indices, low bioavailability, high-dose requirements, lack of specificity, and development of multi-drug resistance. 2 Recent advances in nanotechnology enabled nanoparticle (NP)-based drug formulations to be designed with superior properties compared to traditional small molecule chemotherapy, including high drug loading, specific targeting/delivery, and the ability to regulate the release of the anticancer drug in a controlled or sustained manner. 3 During the last 30 years, many nanomedicines were designed and tested to be effective in reducing the size of various tumor types in laboratory animals, 4,5 but only a limited number of nanomedicines have been translated to clinical success and approved by the United States Food and Drug Administration (US FDA) or European Medicines Agency (EMA). 6 Low clinical translation of animal results -Abstract Truncated-

An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice

Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models

Predicting Nanoparticle Delivery to Tumors Using Machine Learning and Artificial Intelligence Approaches

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer

Physiologically Based Pharmacokinetic Modeling of Nanoparticle Biodistribution: A Review of Existing Models, Simulation Software, and Data Analysis Tools

Drug-loaded nanoparticles for cancer therapy: a high-throughput multicellular agent-based modeling study

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids

Prediction of Drug Distribution in Subcutaneous Xenografts of Human Tumor Cell Lines and Healthy Tissues in Mouse: Application of the Tissue Composition-Based Model to Antineoplastic Drugs

Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response

Deep Learning-Based Artificial Intelligence to Investigate Targeted Nanoparticles’ Uptake in TNBC Cells

Application of High-Z Gold Nanoparticles in Targeted Cancer Radiotherapy—Pharmacokinetic Modeling, Monte Carlo Simulation and Radiobiological Effect Modeling

On the additive artificial intelligence-based discovery of nanoparticle neurodegenerative disease drug delivery systems

PREPRINT Machine Learning for the Sensitivity Analysis of a Model of the Cellular Uptake of Nanoparticles for the Treatment of Cancer

Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of in Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.

Quantitative Imaging of Intracellular Nanoparticle Exposure Enables Prediction of Nanotherapeutic Efficacy

Enhancing Drug Penetration in Solid Tumors Via Nanomedicine: Evaluation Models, Strategies and Perspectives